Navigation Links
Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
Date:9/10/2009

nd exclusively to surface receptors on cancer cells.

About Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is developing a new class of highly potent targeted anticancer drugs using its Cationic Lytic Peptide (CLYP(TM)) platform technology. These drug candidates, called targeted membrane-disrupting peptides (tMDPs), consist of a ligand component that binds to extracellular receptors on the cancer cell and a potent cytolytic peptide component that kills the cancer cell. Targeted MDPs, which are positively charged, specifically bind only to cancer cells that express the target receptors on their surfaces and interact with the negatively charged membranes of the cancer cells resulting in disruption of the cell membrane and causing the cancer cells to die by cell lysis. The drug candidates selectively kill cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. In addition to EP-100, Esperance Pharmaceuticals has three other drug candidates in preclinical stages. The Company was founded on patented technology discovered by scientists at Louisiana State University. Founding investors include the Louisiana Fund I, Research Corporation Technologies and Themelios Ventures, LP -- a venture fund managed by the principals of VCE Capital Partners, LLC. Additional investors include the Louisiana Technology Fund and private investors. More information can be found at www.esperancepharma.com.


'/>"/>
SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, ... Family purchased a DNA test to unravel ... with a lifetime of memories, sharing, and closeness. In ... DNA genuinely brought the family closer together. , ... genetic history and prior to taking the genetic ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... , BEIJING, Sept. 16 ... hospital groups, has announced it will broaden inclusion,criteria ... study will use,stem cells derived from peripheral blood ... of diabetic foot ulcers involves intensive,wound management, risk ...
... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... from the U.S. Food and Drug Administration (FDA) for ...
... , , , SAN ... it is relaunching its oligonucleotide radiolabeling services. TriLink discontinued the ... that the market may no longer require it. However, strong ... in September 2009. , , "We,ve learned ...
Cached Biology Technology:Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 2Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 3Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 4AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services 2
(Date:7/14/2014)... an inevitable consequence of aging? , Although it is ... aging, the risk of developing several common cancers decreases ... the apparent decrease with age in the risk of ... to this puzzle was presented in a recent paper ... Professor James P. Brody of the Department of Biomedical ...
(Date:7/14/2014)... make in the laboratory all of the different types of ... reality. , Writing today in the journal Nature Communications ... researcher Igor Slukvin reports the discovery of two genetic programs ... both red and the array of white cells that make ... identifies how nature itself makes blood products at the earliest ...
(Date:7/11/2014)... from the Wildlife Conservation Society shows that no-take ... valuable species such as lobster, conch, and fish ... nearby reef areas. , The reporttitled "Review of ... of research literature from no-take areas around the ... Dahlgren, a recognized expert in marine protected areas ...
Breaking Biology News(10 mins):Wisconsin scientists find genetic recipe to turn stem cells to blood 2Wisconsin scientists find genetic recipe to turn stem cells to blood 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2
... space activities, a silent revolution is taking place at ... first human-rated spacecraft to be launched from Europe,s Spaceport, ... pressurised module of the largest, most complex automated spacecraft ... fulfilling the most stringent rules of human spaceflight. , ...
... to pass genes to the next generation. In sexually ... that are vital for fertility. In a new study ... researchers at Cornell University knocked down the levels of ... the males abilities to modulate egg production, sperm storage ...
... Washington University School of Medicine in St. Louis have ... plague women with urinary tract infections (UTIs) are entrenched ... controversial revision of scientists, model of how bacteria cause ... for infections get into the bladder but do not ...
Cached Biology News:Final preparations for first human-rated spacecraft to be lauched from Europe's Spaceport 2Final preparations for first human-rated spacecraft to be lauched from Europe's Spaceport 3Bacteria that cause urinary tract infections invade bladder cells 2Bacteria that cause urinary tract infections invade bladder cells 3
...
...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Poly A Polymerase catalyzes the addition of AMP to the 3' hydroxyl terminus of RNA. Poly A Polymerase can add poly(C) and poly(U) to RNA but does so with much-reduced efficiency....
Biology Products: